# INTERCEPT PHARMACEUTICALS IN (ICPT)

> Institutional ownership reported to the SEC as of Q3 2023, from Form 13F filings. Source: https://holderbook.com/stocks/ICPT/

- Reporting holders: 156
- Reported value: $816.6M
- Held through calls: 2.8%
- Held through puts: 8.3%

A 13F reports long US equity positions only. Shorts, bonds, foreign listings and cash are not visible here, and positions are disclosed up to 45 days after the quarter ends.

## Largest holders

| Manager | Value | Shares | Share of their book | Quarters held |
|---|---|---|---|---|
| [BlackRock Inc.](https://holderbook.com/funds/1364742-blackrock-inc/) | $78.1M | 4,212,820 | 0.0% | 20 |
| [STATE STREET CORP](https://holderbook.com/funds/93751-state-street-corp/) | $59.3M | 3,197,810 | 0.0% | 20 |
| [UBS Group AG](https://holderbook.com/funds/1610520-ubs-group-ag/) | $55.8M | 2,999,188 | 0.0% | 20 |
| [Magnetar Financial LLC](https://holderbook.com/funds/1352851-magnetar-financial-llc/) | $44.6M | 2,407,209 | 1.1% | 1 |
| [ALPINE ASSOCIATES MANAGEMENT INC.](https://holderbook.com/funds/1396835-alpine-associates-management-inc/) | $40.8M | 2,203,295 | 2.1% | 1 |
| [DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C)](https://holderbook.com/funds/1009258-deerfield-management-company-l-p-series-c/) | $38.5M | 2,077,893 | 0.8% | 2 |
| [VANGUARD GROUP INC](https://holderbook.com/funds/102909-vanguard-group-inc/) | $38.4M | 2,071,232 | 0.0% | 20 |
| [Jefferies Financial Group Inc.](https://holderbook.com/funds/96223-jefferies-financial-group-inc/) | $37.1M | 2,000,000 | 0.3% | 1 |
| [ALLIANCEBERNSTEIN L.P.](https://holderbook.com/funds/1109448-alliancebernstein-l-p/) | $28.6M | 1,542,896 | 0.0% | 20 |
| [Pictet Asset Management Holding SA](https://holderbook.com/funds/1993888-pictet-asset-management-holding-sa/) | $22.3M | 1,205,093 | 0.0% | 1 |
| [Caligan Partners LP](https://holderbook.com/funds/1727492-caligan-partners-lp/) | $22.2M | 0 | 10.2% | 2 |
| [Rockefeller Capital Management L.P.](https://holderbook.com/funds/1739439-rockefeller-capital-management-l-p/) | $19.2M | 1,037,763 | 0.1% | 15 |
| [GOLDMAN SACHS GROUP INC](https://holderbook.com/funds/886982-goldman-sachs-group-inc/) | $18.9M | 1,019,073 | 0.0% | 20 |
| [BOOTHBAY FUND MANAGEMENT, LLC](https://holderbook.com/funds/1549230-boothbay-fund-management-llc/) | $15.7M | 0 | 0.4% | 6 |
| [RENAISSANCE TECHNOLOGIES LLC](https://holderbook.com/funds/1037389-renaissance-technologies-llc/) | $15.3M | 825,800 | 0.0% | 9 |
| [GEODE CAPITAL MANAGEMENT, LLC](https://holderbook.com/funds/1214717-geode-capital-management-llc/) | $14.7M | 793,321 | 0.0% | 20 |
| [D. E. Shaw & Co., Inc.](https://holderbook.com/funds/1009207-d-e-shaw-co-inc/) | $14.7M | 791,335 | 0.0% | 5 |
| [SUSQUEHANNA INTERNATIONAL GROUP, LLP](https://holderbook.com/funds/1446194-susquehanna-international-group-llp/) | $13.8M | 366,014 | 0.0% | 20 |
| [AQR Arbitrage LLC](https://holderbook.com/funds/1167456-aqr-arbitrage-llc/) | $13.6M | 734,970 | 0.6% | 1 |
| [Balyasny Asset Management L.P.](https://holderbook.com/funds/1218710-balyasny-asset-management-l-p/) | $13.0M | 0 | 0.0% | 1 |
| [Samsara BioCapital, LLC](https://holderbook.com/funds/1744967-samsara-biocapital-llc/) | $11.9M | 640,688 | 3.6% | 20 |
| [MORGAN STANLEY](https://holderbook.com/funds/895421-morgan-stanley/) | $10.7M | 576,774 | 0.0% | 24 |
| [HSBC HOLDINGS PLC](https://holderbook.com/funds/873630-hsbc-holdings-plc/) | $8.5M | 456,623 | 0.0% | 1 |
| [Fort Baker Capital Management LP](https://holderbook.com/funds/1688382-fort-baker-capital-management-lp/) | $8.0M | 0 | 0.7% | 1 |
| [ACADIAN ASSET MANAGEMENT LLC](https://holderbook.com/funds/916542-acadian-asset-management-llc/) | $7.6M | 409,183 | 0.0% | 8 |

## Quarter by quarter

| Quarter | Holders | Reported value |
|---|---|---|
| Q3 2023 | 156 | $816.6M |
| Q2 2023 | 129 | $429.3M |
| Q1 2023 | 146 | $407.4M |
| Q4 2022 | 148 | $381.4M |
| Q3 2022 | 155 | $469.2M |
| Q2 2022 | 152 | $373.1M |
| Q1 2022 | 150 | $432.8M |
| Q4 2021 | 154 | $464.6M |
| Q3 2021 | 146 | $371.7M |
| Q2 2021 | 136 | $488.4M |
| Q1 2021 | 157 | $630.6M |
| Q4 2020 | 177 | $765.0M |